Clinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPMN.24

Transcription

1 Clinical Policy: (Cimzia) Reference Number: ERX.SPMN.24 Effective Date: 10/2016 Last Review Date: 12/2016 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Policy/Criteria It is the policy of health plans affiliated with Envolve Pharmacy Solutions TM that certolizumab pegol (Cimzia ) is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Crohn s Disease (must meet all): 1. Prescribed by or in consultation with a gastroenterologist; 3. Diagnosis of moderately to severely active Crohn s disease (CD) and (a or b): a. Has one of the following poor prognostic indicators for CD: i. Age < 18 years; ii. Perianal disease; iii. Upper gastrointestinal tract involvement; iv. Multiple extra-intestinal manifestations; v. Active tobacco use; vi. Perforating (i.e., fistulizing) disease; b. Member has failed one of the following therapies unless intolerant or contraindicated: i. A biologic for CD other than Cimzia; ii. An immunomodulator (e.g., azathioprine, 6-mercaptopurine [6-MP], methotrexate [MTX]) for 3 consecutive months; 4. Member has failed Humira for 3 consecutive months unless intolerant or contraindicated; 5. Prescribed dose of Cimzia does not exceed 400 mg subcutaneously at weeks 0, 2, and B. Rheumatoid Arthritis (must meet all): 1. Prescribed by or in consultation with a rheumatologist; 3. Diagnosis of moderately to severely active rheumatoid arthritis (RA) and one or more of the following: a. At least five inflamed joints; b. Elevation in the erythrocyte sedimentation rate (ESR) and/or serum C-reactive protein (CRP) concentration; c. Positive rheumatoid factor and/or anticyclic citrullinated peptide antibodies; d. Evidence of inflammation on plain radiography of the hands, wrists, or feet, such as osteopenia and/or periarticular swelling; Page 1 of 6

2 4. Member has failed one of the following therapies unless intolerant or contraindicated: a. A biologic for RA other than Cimzia; b. MTX for 3 consecutive months; c. If MTX is not tolerated or contraindicated, sulfasalazine, leflunomide, or hydroxychloroquine for 3 consecutive months; 5. Member has failed Enbrel AND Humira, each for 3 consecutive months unless intolerant or contraindicated; 6. Prescribed dose of Cimzia does not exceed 400 mg subcutaneously at weeks 0, 2, and C. Psoriatic Arthritis (must meet all): 1. Prescribed in consultation with a dermatologist or rheumatologist; 3. Diagnosis of active psoriatic arthritis (PsA); 4. Member has failed one of the following therapies unless intolerant or contraindicated: a. A biologic for PsA other than Cimzia; b. Methotrexate (MTX) for 3 consecutive months; c. If MTX is not tolerated or contraindicated, sulfasalazine, leflunomide, cyclosporine, or azathioprine, for 3 consecutive months; 5. Member has failed Enbrel AND Humira, each for 3 consecutive months unless intolerant or contraindicated; 6. Prescribed dose of Cimzia does not exceed 400 mg subcutaneously at weeks 0, 2, and D. Ankylosing Spondylitis (must meet all): 1. Prescribed by or in consultation with a rheumatologist; 3. Diagnosis of active ankylosing spondylitis (AS); 4. Member has failed one of the following therapies unless intolerant or contraindicated: a. A biologic for AS other than Cimzia; b. Two or more non-steroidal anti-inflammatory drugs (NSAIDs) at maximum tolerated doses, each for 4 weeks; 5. Member has failed Enbrel AND Humira, each for 3 consecutive months unless intolerant or contraindicated; 6. Prescribed dose of Cimzia does not exceed 400 mg subcutaneously at weeks 0, 2, and E. Other diagnoses/indications: Refer to ERX.SPMN.16 - Global Biopharm Policy Page 2 of 6

3 II. Continued Approval A. All Indications (must meet all): 1. Currently receiving medication via health plan benefit or member has previously met all initial approval criteria; 2. Member responding positively to therapy; 3. Prescribed regimen does not exceed 400 mg every 4 weeks. Approval duration: 12 months B. Other diagnoses/indications (must meet 1 or 2): 1. Currently receiving medication via health plan benefit and documentation supports positive response to therapy; or 2. Refer to ERX.SPMN.16 - Global Biopharm Policy. Background Description/Mechanism of Action: Cimzia (certolizumab pegol) is a TNF blocker. pegol binds to human TNFα with a KD of 90pM. TNFα is a key pro-inflammatory cytokine with a central role in inflammatory processes. pegol selectively neutralizes TNFα (IC90 of 4 ng/ml for inhibition of human TNFα in the in vitro L929 murine fibrosarcoma cytotoxicity assay) but does not neutralize lymphotoxin α (TNFb). pegol cross-reacts poorly with TNF from rodents and rabbits, therefore in vivo efficacy was evaluated using animal models in which human TNFα was the physiologically active molecule. pegol was shown to neutralize membrane-associated and soluble human TNFα in a dose-dependent manner. Incubation of monocytes with certolizumab pegol resulted in a dose-dependent inhibition of LPS-induced TNFα and IL-1b production in human monocytes. pegol does not contain a fragment crystallizable (Fc) region, which is normally present in a complete antibody, and therefore does not fix complement or cause antibody-dependent cell-mediated cytotoxicity in vitro. It does not induce apoptosis in vitro in human peripheral blood-derived monocytes or lymphocytes, nor does certolizumab pegol induce neutrophil degranulation. A tissue reactivity study was carried out ex vivo to evaluate potential cross-reactivity of certolizumab pegol with cryosections of normal human tissues. pegol showed no reactivity with a designated standard panel of normal human tissues. Formulations: Cimzia is supplied as either a sterile, white, lyophilized powder for solution or as a sterile, solution in a single-use prefilled 1 ml glass syringe for subcutaneous injection. After reconstitution of the lyophilized powder with 1 ml sterile Water for Injection, USP, the resulting ph is approximately 5.2. Each single-use vial provides approximately 200 mg certolizumab pegol, 0.9 mg lactic acid, 0.1 mg polysorbate, and 100 mg sucrose. Each single-use prefilled syringe of Cimzia delivers 200 mg in 1 ml of solution with a ph of approximately 4.7 for subcutaneous use. Each 1 ml syringe of Cimzia contains certolizumab pegol (200 mg), sodium acetate (1.36 mg), sodium chloride (7.31 mg), and Water for Injection, USP. Cimzia is a clear to opalescent solution that is colorless to pale yellow and essentially free from particulates. No preservatives are present. Page 3 of 6

4 FDA Approved Indications: Cimzia is a tumor necrosis factor (TNF) blocker/subcutaneous injectable formulation indicated for: Crohn s disease o Reducing signs and symptoms of Crohn s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid arthritis o Treatment of adults with moderately to severely active rheumatoid arthritis (RA). Psoriatic arthritis o Treatment of adult patients with active psoriatic arthritis (PsA). Ankylosing spondylitis o Treatment of adults with active ankylosing spondylitis (AS). Appendices Appendix A: Abbreviation Key 6-MP: 6-mercaptopurine AS: ankylosing spondylitis CRP: serum C-reactive protein CCP: anticyclic citrullinated peptide DMARD: disease modifying antirheumatic drug ESR: erythrocyte sedimentation rate MTX: methotrexate NSAID: non-steroidal anti-inflammatory drug PsA: psoriatic arthritis RA: rheumatoid arthritis TB: tuberculosis TNF: tumor necrosis factor Coding Implications Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-todate sources of professional coding guidance prior to the submission of claims for reimbursement of covered services. HCPCS Codes J0717 Description Injection, certolizumab pegol, 1 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) Reviews, Revisions, and Approvals Date Approval Date Policy split from USS.SPMN.24 Irritable Bowel Disease (IBD) Treatments, USS.SPMN.41 Psoriasis Treatments, and USS.SPMN.44 Rheumatoid Arthritis and Ankylosing Spondylitis Treatments. Converted to new template. Removed all safety criteria. Added dosing criteria per PI. Added requirement for trial and failure of PDL Enbrel and Humira, unless contraindicated (just Humira for CD). 08/16 09/16 Page 4 of 6

5 Reviews, Revisions, and Approvals Date Approval Date -CD: removed aminosalicylate as an option for initial therapy per 2013 Gastro Clinical Decision Tool. -RA: added age requirement per PI; modified criteria to require trial of methotrexate, unless contraindicated; added sulfasalazine and hydroxychloroquine as an alternative to methotrexate if methotrexate is contraindicated. -AS: removed question about axial vs peripheral disease; removed requirement for trial of methotrexate or sulfasalazine. For all trial/failure requirements, indicated that member can also meet criteria if intolerant (as opposed to just contraindicated) to therapy in question. Modified the following initial criteria sets: -RA: indicated that disease must be moderately to severely active. -PsA: modified trial/failure requirement- instead of requiring 2 or more nonbiologic DMARDs (such as cyclosporine, sulfasalazine, azathioprine, hydoxychloroquine), criteria now requires MTX. If MTX is contraindicated, then cyclosporine, sulfasalazine, leflunomide, cyclosporine, or azathioprine may be trialed. -CD: removed option for trial/failure of corticosteroid. 11/16 12/16 References 1. Cimzia Prescribing Information. Smyrna, GA: UCB, Inc.; April Available at Accessed June 23, Lichtenstein GR, Hanauer SB, Sandborn WJ, and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn s disease in adults. Am J Gastroenterol. 2009;104(2): Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73: Singh JA, Furst DE, Bharat A, et al update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012; 64(5): Schur PH, Cohen S. Initial treatment of moderately to severely active rheumatoid arthritis in adults. In: UpToDate, Waltham, MA: Walters Kluwer Health; Available at: Accessed June 14, Cohen S, Cannella A. Treatment of rheumatoid arthritis in adults resistant to initial nonbiologic DMARD therapy. In: UpToDate, Waltham, MA: Walters Kluwer Health; Available at: Accessed June 14, Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1): Page 5 of 6

6 8. Menter A, Gottlieb A, Feldman SR, et al. Guidelines for the management of psoriasis and psoriatic arthritis. Section 1: Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5): Gladman DD, Ritchlin C. Treatment of psoriatic arthritis. In: UpToDate, Waltham, MA: Walters Kluwer Health; Available at Accessed June 16, Feldman SR. Treatment of psoriasis. In: UpToDate, Waltham, MA: Walters Kluwer Health; Available at Accessed June 15, Ward MM, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis & Rheumatology, DOI /ART Braun J, van den berg R, et al Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Am Rheu Dis. 2011: 70; Sandborn WJ. Crohn s Disease Evaluation and Treatment: Clinical Decision Tool. Gastroenterology 2014; 147: Singh JA. Saag KG, Bridges SL, et al American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research. 2015; DOI /acr Important Reminder This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein. Page 6 of 6